| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.
|
Science
|
2005
|
5.20
|
|
2
|
Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.
|
Nat Neurosci
|
2010
|
2.90
|
|
3
|
Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1.
|
Trends Neurosci
|
2009
|
2.55
|
|
4
|
Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory.
|
Nat Neurosci
|
2008
|
2.29
|
|
5
|
Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1.
|
J Neurosci
|
2008
|
2.04
|
|
6
|
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
|
J Pharmacol Exp Ther
|
2008
|
1.81
|
|
7
|
The genetics and biology of DISC1--an emerging role in psychosis and cognition.
|
Biol Psychiatry
|
2006
|
1.79
|
|
8
|
Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity.
|
J Neurosci
|
2009
|
1.52
|
|
9
|
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
|
J Pharmacol Exp Ther
|
2009
|
1.35
|
|
10
|
DISC1 at 10: connecting psychiatric genetics and neuroscience.
|
Trends Mol Med
|
2011
|
1.34
|
|
11
|
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
|
Mol Cell Neurosci
|
2009
|
1.16
|
|
12
|
The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.
|
J Pharmacol Exp Ther
|
2008
|
1.15
|
|
13
|
Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia.
|
J Neurosci
|
2010
|
1.15
|
|
14
|
Estrogen receptor ß activity modulates synaptic signaling and structure.
|
J Neurosci
|
2010
|
1.15
|
|
15
|
GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.
|
Neuropharmacology
|
2009
|
1.09
|
|
16
|
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
|
ACS Chem Neurosci
|
2014
|
1.06
|
|
17
|
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
|
Drug Metab Dispos
|
2012
|
1.02
|
|
18
|
Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1.
|
Proc Natl Acad Sci U S A
|
2005
|
0.99
|
|
19
|
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.
|
Proc Natl Acad Sci U S A
|
2010
|
0.99
|
|
20
|
DISC1 and DISC2: discovering and dissecting molecular mechanisms underlying psychiatric illness.
|
Ann Med
|
2004
|
0.98
|
|
21
|
How has DISC1 enabled drug discovery?
|
Mol Cell Neurosci
|
2007
|
0.94
|
|
22
|
Fyn kinase contributes to tyrosine phosphorylation of the GABA(A) receptor gamma2 subunit.
|
Mol Cell Neurosci
|
2010
|
0.93
|
|
23
|
A cell-based ultra-high-throughput screening assay for identifying inhibitors of D-amino acid oxidase.
|
J Biomol Screen
|
2006
|
0.90
|
|
24
|
Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders.
|
Curr Mol Pharmacol
|
2009
|
0.88
|
|
25
|
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
|
J Med Chem
|
2010
|
0.87
|
|
26
|
Disrupted in Schizophrenia 1 forms pathological aggresomes that disrupt its function in intracellular transport.
|
Hum Mol Genet
|
2012
|
0.86
|
|
27
|
Regulation of the cytoskeleton by Disrupted-in-schizophrenia 1 (DISC1).
|
Mol Cell Neurosci
|
2011
|
0.84
|
|
28
|
What can we learn from the disrupted in schizophrenia 1 interactome: lessons for target identification and disease biology?
|
Novartis Found Symp
|
2008
|
0.84
|
|
29
|
Assessing the role of endooligopeptidase activity of Ndel1 (nuclear-distribution gene E homolog like-1) in neurite outgrowth.
|
Mol Cell Neurosci
|
2010
|
0.82
|
|
30
|
Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
|
J Med Chem
|
2011
|
0.81
|
|
31
|
Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals.
|
Prog Brain Res
|
2009
|
0.80
|
|
32
|
d-amino acid oxidase knockout (Dao(-/-) ) mice show enhanced short-term memory performance and heightened anxiety, but no sleep or circadian rhythm disruption.
|
Eur J Neurosci
|
2015
|
0.79
|
|
33
|
Future viable models of psychiatry drug discovery in pharma.
|
J Biomol Screen
|
2013
|
0.78
|
|
34
|
Increased burst-firing of ventral tegmental area dopaminergic neurons in D-amino acid oxidase knockout mice in vivo.
|
Eur J Neurosci
|
2014
|
0.77
|
|
35
|
D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone.
|
J Biol Chem
|
2011
|
0.77
|
|
36
|
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
|
ACS Chem Biol
|
2014
|
0.76
|
|
37
|
Disrupted in schizophrenia 1 and synaptic function in the mammalian central nervous system.
|
Eur J Neurosci
|
2014
|
0.76
|
|
38
|
Identification and characterisation of a Maf1/Macoco protein complex that interacts with GABAA receptors in neurons.
|
Mol Cell Neurosci
|
2010
|
0.75
|
|
39
|
Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
|
Bioorg Med Chem Lett
|
2012
|
0.75
|